China SXT Pharmaceuticals (SXTC) Accounts Payables (2018 - 2026)

China SXT Pharmaceuticals has reported Accounts Payables for 9 years, with the latest figure at $497648.0 in Q1 2026.

• On a quarterly basis, Accounts Payables fell 57.04% year-over-year to $497648.0 in Q1 2026; TTM through Mar 2026 was $497648.0, a 57.04% decrease from a year earlier, with the FY2026 full-year figure at $497648.0, down 57.04% from the prior year.
• Accounts Payables was $497648.0 for Q1 2026 at China SXT Pharmaceuticals, down from $530662.0 in the prior quarter.
• The five-year high for Accounts Payables was $1.7 million in Q3 2024, with the low at $497648.0 in Q1 2026.
• Average Accounts Payables over 5 years is $1.2 million, with a median of $1.3 million recorded in 2023.
• The sharpest annual moves came in 2024 and 2025: Accounts Payables gained 26.36% in 2024, then tumbled 68.08% in 2025.
• Over 5 years, Accounts Payables stood at $1.6 million in 2022, then declined by 15.72% to $1.3 million in 2023, then advanced by 26.36% to $1.7 million in 2024, then sank by 68.08% to $530662.0 in 2025, then dropped by 6.22% to $497648.0 in 2026.
• The last three Accounts Payables figures came in at $497648.0 (Q1 2026), $530662.0 (Q3 2025), and $1.2 million (Q1 2025), per Business Quant data.